Jefferies analyst Matthew Taylor maintained a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report) today and set a price target of $95.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Matthew Taylor’s rating is based on GE Healthcare Technologies Inc’s strong performance in the first quarter, where the company reported sales and earnings per share that exceeded expectations. The company achieved a record growth in orders, which increased by 10% year-over-year, and maintained a healthy book-to-bill ratio, indicating strong demand for its products. Despite the challenges posed by tariffs and issues in China, GE Healthcare has managed these effectively, adopting a conservative approach that has mitigated potential negative impacts.
Additionally, GE Healthcare’s management has demonstrated resilience and adaptability, with no significant cancellations or deferrals in orders, particularly in imaging, which remains a priority for hospitals due to its solid return on investment. The company’s guidance for future margins and earnings per share, although adjusted to account for tariffs, reflects a stable outlook. Furthermore, GE Healthcare’s strategic initiatives, such as expanding its network of contract manufacturing organizations and commercializing new products, are expected to drive future revenue growth. These factors combined have led Matthew Taylor to maintain a Buy rating for the stock.
Taylor covers the Healthcare sector, focusing on stocks such as Boston Scientific, Edwards Lifesciences, and Dexcom. According to TipRanks, Taylor has an average return of 7.3% and a 55.05% success rate on recommended stocks.
In another report released yesterday, Citi also reiterated a Buy rating on the stock with a $86.00 price target.